Patiromer Enables Sustained RAAS Inhibitor Therapy over 52 Weeks: A Post Hoc Analysis of 246 Patients Who Completed the AMETHYST-DN Study: PO2370

Journal article

Peer reviewed

Murray Epstein, Susan Arthur and Jeffrey J. Budden

Journal of the American Society of Nephrology, Vol.32(10S), pp.726-727

2021-10

Metrics

1 Record Views

Title: Patiromer Enables Sustained RAAS Inhibitor Therapy over 52 Weeks: A Post Hoc Analysis of 246 Patients Who Completed the AMETHYST-DN Study
Creators: Murray Epstein - University of Miami
Susan Arthur - Vifor Pharma (United States)
Jeffrey J. Budden - Vifor Pharma (United States)
Publication Details: Journal of the American Society of Nephrology, Vol.32(10S), pp.726-727
Number of pages: 2
Academic Unit: Benefits - Other; Human Resources
Language: English
Resource Type: Journal article
Record Identifier: 991032860736702976